Importantly, when combined with anti-PD-L1 therapy, VSVM51R-Neo−2/15 produced synergistic antitumor effects, resulting in improved tumor regression, survival, and the induction of long-term antitumor immunity. This evidence concerns the gene CD274 and neoplasm.